Drug Trial Radar · NCT05312710
Safety and Efficacy of APG-157 in Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 22, 2022
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Aveta Biomics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.
Conditions
- Head and Neck Cancer
- Squamous Cell Carcinoma of Oral Cavity
- Squamous Cell Carcinoma of the Oropharynx
Interventions
APG-157Drug
Treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Imaging to assess drug's ability to impact tumor sizeTime frame: Baseline to end of dosing is four weeks (extendable up to 6 weeks) of APG-157 dosing. Baseline is at time of diagnosis. End of dosing is day before surgery or start of other definitive therapy and/or radiation
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
VAGLAHS, West Los Angeles
Los Angeles, California
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.